Cordlife P8A

SGD 0.091 +0.00% +0.00 Updated 17 Nov 2026, 17:16 SGT

Company profile

The business, the people and the ownership behind Cordlife.

Business overview

About the company

Cordlife Group provides private cord blood banking services in Asia. Its business focuses on services supporting mothers and children through its network of cord blood banking facilities.

Annual Report 2025 ↗ Reviewed 2026-10-23 · Source dated 2026-04-09. PDF p. 5

Listed security

Company & listing

Full Company Name
CORDLIFE GROUP LIMITED
Trading Currency
SGD
Website
www.cordlife.com…/sg
Listing
Listed on 29 March 2012 on SGX Mainboard
ISIN Code
SG2E64980112

Board & management

Leadership

Eight annual-report Board members, one separate Group CFO and the named annual-report secretary. Chen Xiaoling’s Group CEO, Singapore CEO and Executive Director roles refer to one person.

The annual report names Goh Xun Er as Company Secretary. Official announcement dated 15 July 2026 replaces her with Hon Wei Ling and states the two Company Secretaries are Cheok Hui Yee and Hon Wei Ling. The historical annual role is explicitly qualified with this later change.

Mr Wu Gang

Non-Independent Non-Executive Chairman

Appointed 2 December 2025; annual-report Board.

Ms Chen Xiaoling

Group Chief Executive Officer, Group Executive Director

Group CEO and CEO of Singapore from 5 June 2025; Group Executive Director from 17 July 2024. Single person with multiple roles.

Mr Yiu Ming Yiu

Non-Independent Non-Executive Director

Annual-report Board; appointed 1 December 2021.

Dr Xu Tianhong

Independent Director

Annual-report Board; appointed 14 May 2024.

Mr Gao Xiang

Independent Director

Annual-report Board; appointed 14 November 2024; Audit and Risk Committee chairman in corporate governance report.

Mr Sim Sze Kuan

Independent Director

Annual-report Board; appointed 14 November 2024.

Dr Wang Xiaorui

Independent Director

Annual-report Board; appointed 14 November 2024.

Ms Yuen Wai

Independent Director

Annual-report Board; appointed 19 February 2025.

Ms Wu Yifei

Group Chief Financial Officer

Key executive; appointed 14 August 2025. Not an additional director.

Ms Goh Xun Er

Company Secretaries

Historical FY2025 annual-report role. Replaced by Hon Wei Ling effective 15 July 2026; official announcement states Company Secretaries thereafter are Cheok Hui Yee and Hon Wei Ling. Do not present Goh as current.

Roles listed in Annual Report 2025; current appointments are not independently verified.

Holdings

Ownership

Twenty registered/depository accounts and seventeen printed substantial-shareholder register rows at 20 March 2026 are retained, with eight capital/distribution/free-float contexts. Eligible shares 256,307,744 exclude 11,217,610 treasury shares; no subsidiary holdings.

Direct/deemed interests of Nanjing/Sanpower/Yuan, TransGlobal/Lui/Yiu, Ally Honour/Cedar Tree/Chen Yi Dan and Matinal/Kang overlap common blocks. They are not additive. Cedar Tree and Chen Yi Dan remain in the original substantial register at printed 4.99%.

Seven original rows for the Robust Plan upstream chain each show 15,920,000 deemed shares / 6.21%; original footnotes (8)–(14) state the downstream holder ceased substantial status on 24 January 2024. These are explicitly retained as historical register disclosures with a source inconsistency, not current beneficial holdings. The same source separately states the GCBC chain was removed after its 2024 disposal.

Top twenty total 235,865,920 / 92.02%; public float approximately 41.62% is a distinct measure. Original names and source spelling, including China Minsheng Investment Cop., Ltd, are retained.

Nanjing Xinjiekou Department Store Co., Ltd.

Direct 51,870,000 shares; 20.24%; deemed — shares; —

At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice.

Sanpower Group Corporation

20.24%Total interest

Direct — shares—deemed 51,870,000 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice.

Yuan Yafei

20.24%Total interest

Direct — shares—deemed 51,870,000 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice.

TransGlobal Real Estate Group Limited

Direct 71,460,300 shares; 27.88%; deemed — shares; —

At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice.

Lui Yim Sheung

27.88%Total interest

Direct — shares—deemed 71,460,300 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice.

Yiu Chi Shing

27.88%Total interest

Direct — shares—deemed 71,460,300 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice.

Cedar Tree Investment Ltd

4.99%Total interest

Direct — shares—deemed 12,800,000 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice. Cedar Tree/Chen Yi Dan’s 12,800,000 deemed shares are the same block held by registered Ally Honour Trading (HK) Limited; printed register includes this 4.99% row.

Chen Yi Dan

4.99%Total interest

Direct — shares—deemed 12,800,000 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice. Cedar Tree/Chen Yi Dan’s 12,800,000 deemed shares are the same block held by registered Ally Honour Trading (HK) Limited; printed register includes this 4.99% row.

Matinal Best Limited

Direct 26,202,866 shares; 10.22%; deemed — shares; —

At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice.

Kang Lan

10.22%Total interest

Direct — shares—deemed 26,202,866 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice.

Jiaxing Huiling No. 3 Investment Partnership (Limited Partnership)

6.21%Total interest

Direct — shares—deemed 15,920,000 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice. Original inconsistency: footnotes (8)–(14) on physical page 126 explicitly state Robust Plan Limited ceased to be a substantial shareholder on 24 January 2024, and its upstream chain ceased or is based on historical forms. This printed 15,920,000-share/6.21% row is retained as a historical register disclosure, not asserted as a current stake.

Minsheng (Shanghai) Asset Management Co., Ltd.

6.21%Total interest

Direct — shares—deemed 15,920,000 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice. Original inconsistency: footnotes (8)–(14) on physical page 126 explicitly state Robust Plan Limited ceased to be a substantial shareholder on 24 January 2024, and its upstream chain ceased or is based on historical forms. This printed 15,920,000-share/6.21% row is retained as a historical register disclosure, not asserted as a current stake.

China Minsheng Investment Cop., Ltd

6.21%Total interest

Direct — shares—deemed 15,920,000 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice. Original inconsistency: footnotes (8)–(14) on physical page 126 explicitly state Robust Plan Limited ceased to be a substantial shareholder on 24 January 2024, and its upstream chain ceased or is based on historical forms. This printed 15,920,000-share/6.21% row is retained as a historical register disclosure, not asserted as a current stake.

Jiaxing Huiling Capital Management Co., Ltd

6.21%Total interest

Direct — shares—deemed 15,920,000 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice. Original inconsistency: footnotes (8)–(14) on physical page 126 explicitly state Robust Plan Limited ceased to be a substantial shareholder on 24 January 2024, and its upstream chain ceased or is based on historical forms. This printed 15,920,000-share/6.21% row is retained as a historical register disclosure, not asserted as a current stake.

CMI Capital Co., Ltd

6.21%Total interest

Direct — shares—deemed 15,920,000 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice. Original inconsistency: footnotes (8)–(14) on physical page 126 explicitly state Robust Plan Limited ceased to be a substantial shareholder on 24 January 2024, and its upstream chain ceased or is based on historical forms. This printed 15,920,000-share/6.21% row is retained as a historical register disclosure, not asserted as a current stake.

Vcanland Holding Group Company Limited

6.21%Total interest

Direct — shares—deemed 15,920,000 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice. Original inconsistency: footnotes (8)–(14) on physical page 126 explicitly state Robust Plan Limited ceased to be a substantial shareholder on 24 January 2024, and its upstream chain ceased or is based on historical forms. This printed 15,920,000-share/6.21% row is retained as a historical register disclosure, not asserted as a current stake.

Li Defu

6.21%Total interest

Direct — shares—deemed 15,920,000 shares
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice. Original inconsistency: footnotes (8)–(14) on physical page 126 explicitly state Robust Plan Limited ceased to be a substantial shareholder on 24 January 2024, and its upstream chain ceased or is based on historical forms. This printed 15,920,000-share/6.21% row is retained as a historical register disclosure, not asserted as a current stake.

Number of equity securities

256,307,744 ordinary shares (excluding treasury shares)

Shareholder percentage denominator.

Number of treasury shares

11,217,610 ordinary shares

Treasury shares excluded from voting/ownership denominator.

Class of equity securities

Ordinary Shares

No par value, as also stated in Note 23 physical page 100.

Voting rights

one vote per share

Ordinary issued shares; treasury excluded.

TOTAL

1,340 shareholders; 256,307,744 shares

Original size-distribution totals.

subsidiary holdings

does not have any subsidiary holdings

Explicit nil disclosure under note (1).

TOTAL

92.02%Total interest

235,865,920 shares
Twenty largest registered/depository accounts; distinct from beneficial ownership and public float.

FREE FLOAT

41.62%

Approximately 41.62% held in public hands at 20 March 2026. Not equal to shares outside the top twenty.

Total interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.

Registered & depository holders 20 holders

Registered holdings, including nominees and depositories; these do not establish ultimate beneficial ownership. As reported at 2026-03-20 · PDF p. 127

Registered holderInterestShares / unitsSource
PHILLIP SECURITIES PTE LTD113,730,277 shares; 44.37%PDF p. 1272026-03-20
CITIBANK NOMS SPORE PTE LTD74,940,873 shares; 29.24%PDF p. 1272026-03-20
ALLY HONOUR TRADING (HK) LIMITED12,800,000 shares; 4.99%PDF p. 1272026-03-20
DBS NOMINEES PTE LTD9,879,709 shares; 3.85%PDF p. 1272026-03-20
MAYBANK SECURITIES PTE. LTD.9,485,160 shares; 3.70%PDF p. 1272026-03-20
COOP INTERNATIONAL PTE LTD3,107,000 shares; 1.21%PDF p. 1272026-03-20
TANTALUM CELLULAR PRODUCTS LLC2,566,972 shares; 1.00%PDF p. 1272026-03-20
HENRY NGO1,700,000 shares; 0.66%PDF p. 1272026-03-20
TAN POH LAN1,165,680 shares; 0.45%PDF p. 1272026-03-20
UNITED OVERSEAS BANK NOMINEES P L990,550 shares; 0.39%PDF p. 1272026-03-20
THET HNIN YI866,920 shares; 0.34%PDF p. 1272026-03-20
RAFFLES NOMINEES(PTE) LIMITED837,829 shares; 0.33%PDF p. 1272026-03-20
ALLSLAND PTE LTD809,800 shares; 0.32%PDF p. 1272026-03-20
OCBC NOMINEES SINGAPORE PTE LTD635,000 shares; 0.25%PDF p. 1272026-03-20
LIM AND TAN SECURITIES PTE LTD515,000 shares; 0.20%PDF p. 1272026-03-20
LEE IN CHUN487,200 shares; 0.19%PDF p. 1272026-03-20
UOB KAY HIAN PTE LTD363,000 shares; 0.14%PDF p. 1272026-03-20
MOOMOO FINANCIAL SINGAPORE PTE. LTD.332,000 shares; 0.13%PDF p. 1272026-03-20
CHOO BOON YONG328,550 shares; 0.13%PDF p. 1272026-03-20
OCBC SECURITIES PRIVATE LTD324,400 shares; 0.13%PDF p. 1272026-03-20

Group structure

Subsidiaries and associates

Sixteen distinct subsidiaries are disclosed in Note28. Macau appears on two original rows held99% through Healthbaby Hong Kong and1% through Cordlife Hong Kong; these routes are combined for one legal entity without double-counting. Both2025/2024 percentages are retained.

Note28 prints99.99% for India/Philippines while the structure chart displays99.9%; retain the detailed note percentages. Stemlife Berhad and its three subsidiaries have99.03% effective interests in the note.

Thai Stemlife is an associate held via Stemlife Berhad. The note prints39.61% Group effective interest, while the chart shows40% direct interest. Shanghai Cordlife Stem Cell Research Co., Ltd is dormant; the official22May2025 notice corrects erroneous Biomedical wording in previous annual reports without changing other information.

CompanyMarketOwnership interest
Cordlife (Hong Kong) LimitedAt 31 December 2025; Cord blood, cord lining, cord tissue banking and diagnostics. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 Hong Kong; equity held 2025 100%; 2024 100%
Cordlife Stem Cell Technology LimitedAt 31 December 2025; Cord lining banking. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 Hong Kong; equity held 2025 100%; 2024 100%
Healthbaby Biotech (Hong Kong) Co., LimitedAt 31 December 2025; Cord blood, cord lining and cord tissue banking. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 Hong Kong; equity held 2025 100%; 2024 100%
Cordlife Technologies Pte. Ltd.At 31 December 2025; Cord lining banking and diagnostics. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 Singapore; equity held 2025 100%; 2024 100%
CS Cell Technologies Pte. Ltd.At 31 December 2025; Investment holding. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 Singapore; equity held 2025 100%; 2024 100%
Stemlife BerhadAt 31 December 2025; Cord blood banking. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 Malaysia; equity held 2025 99.03%; 2024 99.03%
Shanghai Cordlife Stem Cell Research Co., LtdAt 31 December 2025; Dormant. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 People’s Republic of China; equity held 2025 100%; 2024 100%
Cordlife Sciences (India) Pvt. Ltd.At 31 December 2025; Cord blood, cord lining, cord tissue banking and diagnostics. Held by CS Cell Technologies Pte Ltd. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings. Note 28 prints 99.99% in both years; structure chart rounds/displays 99.9%, so the precise note value is retained.PDF p. 106 India; equity held 2025 99.99%; 2024 99.99%
Cordlife Medical Phils., IncAt 31 December 2025; Cord blood, cord lining, cord tissue banking and diagnostics. Held by CS Cell Technologies Pte Ltd. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings. Note 28 prints 99.99% in both years; structure chart rounds/displays 99.9%, so the precise note value is retained.PDF p. 106 Philippines; equity held 2025 99.99%; 2024 99.99%
PT. Cordlife PersadaAt 31 December 2025; Cord blood, cord lining, cord tissue banking and diagnostics. Held by CS Cell Technologies Pte Ltd. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 Indonesia; equity held 2025 67%; 2024 67%
CL Biotech Company LimitedAt 31 December 2025; Consulting, medical/pharmaceutical research and development. Held by CS Cell Technologies Pte Ltd. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 Vietnam; equity held 2025 100%; 2024 100%
Hong Kong Stem Cell Regeneration Company LimitedAt 31 December 2025; Dormant. Held by Cordlife Stem Cell Technology Limited. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 Hong Kong; equity held 2025 100%; 2024 100%
Stemlife Properties Sdn. Bhd.At 31 December 2025; Property investment. Held by Stemlife Berhad. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 Malaysia; equity held 2025 99.03%; 2024 99.03%
Stemlife Therapeutics Sdn. Bhd.At 31 December 2025; Cord lining and cord tissue banking. Held by Stemlife Berhad. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 Malaysia; equity held 2025 99.03%; 2024 99.03%
Stemlife Biotechnology Sdn. Bhd.At 31 December 2025; Medical laboratory, diagnostics and general medical screening. Held by Stemlife Berhad. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 Malaysia; equity held 2025 99.03%; 2024 99.03%
Healthbaby Biotech (Macau) Co., LimitedAt 31 December 2025; Marketing services; original two ownership routes combined for one legal entity. Held by Healthbaby Biotech (Hong Kong) Co., Limited (99%) and Cordlife (Hong Kong) Limited (1%). Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 Macau; equity held 2025 99 + 1%; 2024 99 + 1%
Thai Stemlife Co., LtdHeld by Stemlife Berhad. Cord blood banking services. Structure chart shows direct stake 40%; 40% × 99.03% = 39.612% Group effective holding rounded39.61%. This is an associate, not a subsidiary.PDF p. 87 Thailand; effective ownership 2025 39.61%; 2024 39.61%

Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.

Senior executives

Key management

Key management

ItemValuePeriod / scopeSource
Ms Wu Yifei Group Chief Financial Officer PDF p. 21

Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.

Shareholding statistics

Share capital & shareholders

Share capital

ItemValuePeriod / scopeSource
Number of equity securities 256,307,744 ordinary shares (excluding treasury shares) Company · As at 2026-03-20 PDF p. 125
Class of equity securities Ordinary Shares Company · As at 2026-03-20 PDF p. 125
Voting rights one vote per share Company · As at 2026-03-20 PDF p. 125

Treasury shares

ItemValuePeriod / scopeSource
Number of treasury shares 11,217,610 ordinary shares Company · As at 2026-03-20 PDF p. 125
Subsidiary holdings The Company does not have any subsidiary holdings as at the Latest Practicable Date. Company PDF p. 125

Shareholding distribution

ItemValuePeriod / scopeSource
TOTAL 1,340 shareholders Company · As at 2026-03-20 PDF p. 125
1 - 99 22 holders; 1.64%; 597 shares; 0.00% Company · As at 2026-03-20 PDF p. 125
100 - 1,000 146 holders; 10.90%; 93,493 shares; 0.04% Company · As at 2026-03-20 PDF p. 125
1,001 - 10,000 775 holders; 57.84%; 4,320,259 shares; 1.69% Company · As at 2026-03-20 PDF p. 125
10,001 - 1,000,000 388 holders; 28.95%; 22,517,724 shares; 8.78% Company · As at 2026-03-20 PDF p. 125
1,000,001 and above 9 holders; 0.67%; 229,375,671 shares; 89.49% Company · As at 2026-03-20 PDF p. 125

Free float

ItemValuePeriod / scopeSource
FREE FLOAT [Rule 1207(9) of the Listing Manual] approximately 41.62% of the shareholding in the Company was held in the hands of the public Company · As at 2026-03-20 PDF p. 127
FREE FLOAT [Rule 1207(9) of the Listing Manual] Accordingly, the Company has complied with Rule 723 of the Listing Manual. Company · As at 2026-03-20 PDF p. 127

Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.

Related parties, people & properties

Other disclosures

Related party transactions

ItemValuePeriod / scopeSource
Interested person transactions There were no interested person transactions amounting to S$100,000 or more for the financial year reported on. Group, FY2025 PDF p. 43

Contingent liabilities

ItemValuePeriod / scopeSource
Status of Claims against the Company the Company has received claims from the Company’s customers alleging the damage of cord blood units Company, FY2025 PDF p. 119
Contingent liabilities - financial impact the Company is at present unable to assess the financial impact arising therefrom Group, FY2025 PDF p. 122
Investigation by Commercial Affairs Department the CAD had not imposed any further directives and/or penalties on the Company in relation to the Investigations Company, FY2025 · As at 2025-12-31 PDF p. 122

Director remuneration

ItemValuePeriod / scopeSource
Dr Xu, Tianhong 50,000 S$ Director, FY2025 PDF p. 35
Gao Xiang 50,000 S$ Director, FY2025 PDF p. 35
Dr Wang Xiaorui 50,000 S$ Director, FY2025 PDF p. 35
Sim Sze Kuan 50,000 S$ Director, FY2025 PDF p. 35
Yuen Wai 43,333 S$ Director, FY2025 PDF p. 35
Wu Gang (1) 7,971 S$ Director, FY2025 PDF p. 35
Zhai Lingyun (6) 48,551 S$ Director, FY2025 PDF p. 35
Top three key management personnel aggregate remuneration S$661,343 Top three key management personnel excluding GCEO and ED, FY2025 PDF p. 36

Properties

ItemValuePeriod / scopeSource
Unit 6.06, Wisma Perintis, Jalan Dungun, Damansara Heights, 50490 Freehold Group, investment property, 31 December 2025 · As at 2025-12-31 PDF p. 91
B-1-8, Greentown Square, Jalan Dato Seri Ahmad Said, 30450 Ipoh, Perak Leasehold; 99 years Group, investment property, 31 December 2025 · As at 2025-12-31 PDF p. 91
No. 220, Jalan Burma, 10350 Penang Freehold Group, investment property, 31 December 2025 · As at 2025-12-31 PDF p. 91
B-2-8, Greentown Square, Jalan Dato Seri Ahmad Said, 30450 Ipoh, Perak Leasehold; 99 years Group, investment property, 31 December 2025 · As at 2025-12-31 PDF p. 91
B-3-8, Greentown Square, Jalan Dato Seri Ahmad Said, 30450 Ipoh, Perak Leasehold; 99 years Group, investment property, 31 December 2025 · As at 2025-12-31 PDF p. 91

Subsequent events

ItemValuePeriod / scopeSource
CBBS Licence renewal after year end the Company’s CBBS Licence has been renewed for a period one (1) year from 14 January 2026 to 13 January 2027 (both dates inclusive) Company, after 31 December 2025 PDF p. 121

Outlook

ItemValuePeriod / scopeSource
Group CEO's message - looking ahead the worst is behind us Group CEO, FY2025 report PDF p. 7

Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.

Source: Annual Report 2025 ↗

Corporate information

Registration & contacts

Incorporated In
SINGAPORE
Incorporated On
02 May 2001
Telephone
65 62380808
Fax
65 62381108
Registered Office
1 Yishun Industrial Street 1
#06-01/09, A'POSH BIZHUB
Singapore 768160
Secretary
Cheok Hui Yee
Hon Wei Ling
Registrar / Transfer Agent
ASCENTIUM CORPORATE SERVICES PTE. LTD.
Registrar Address
36 Robinson Road, #20-01 City House, Singapore 068877
Auditors
PKF-CAP LLP
Other Stock Exchange Listings
*SINGAPORE EXCHANGE LTD.
Country
SINGAPORE
Security Type
stocks